col blocks we are bridge builder col blocks
COVID Antworten in den wissenschaftlichen Zeitschriften der Welt


6 Ergebisse       Seite 1

 [1] 
American Society for Pharmacology & Experimental Therapeutics: Molecular Pharmacology
  Original Artikel Datum Titel Autoren   Alle Autoren
1 [GO] 2023―Okt―12 Targeting Cyclophilin A and CD147 to Inhibit Replication of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and SARS-CoV-2-Induced Inflammation Fan Yang, Chenglong Liu, Pengyuan Li, Aihua Wu, Yue Ma-Lauer, Hao Zhang, et al. (+4)
2 [GO] 2022―Feb―01 A Comment on “Remdesivir and EIDD-1931 Interact with Human Equilibrative Nucleoside Transporters 1 and 2: Implications for Reaching SARS-CoV-2 Viral Sanctuary Sites” Eric K. Johnson
3 [GO] 2022―Feb―01 Response to Comments on “Remdesivir and EIDD-1931 Interact with Human Equilibrative Nucleoside Transporters 1 and 2: Implications for Reaching SARS-CoV-2 Viral Sanctuary Sites” Siennah R. Miller, Meghan E. McGrath, Kimberley M. Zorn, Sean Ekins, Stephen H. Wright, Nathan J. Cherrington
4 [GO] 2021―Sep―09 Remdesivir and EIDD-1931 Interact with Human Equilibrative Nucleoside Transporters 1 and 2: Implications for Reaching SARS-CoV-2 Viral Sanctuary Sites Siennah R. Miller, Meghan E. McGrath, Kimberley M. Zorn, Sean Ekins, Stephen H. Wright, Nathan J. CHERRINGTON
5 [GO] 2020―Okt―21 Dysregulation of ACE2 Expression and Function in Co-morbid Disease Conditions Possibly Contributes to COVID-19 Complication Severity Safaa Hammoud, Zena Wehbe, Samar Abdelhady, Firas Kobeissy, Ali Hussein Eid, Ahmed F El-Yazbi
6 [GO] 2020―Sep―10 Heparin-binding peptides as novel therapies to stop SARS-CoV-2 cellular entry and infection Omid Tavassoly, Farinaz Safavi, Iman Tavassoly
 [1] 

6 Ergebisse       Seite 1



[de][en]

Letzte Änderung 2023―Okt―27 12:08:13 UTC

© Daten-Quadrat 2022       Done in 0.005 sec